McNicoll, Lewis & Vlak Maintains Buy Rating and $21 PT on Transcept Pharmaceuticals

A report from MLV & Co reiterates its Buy rating and $21 price target on Transcept Pharmaceuticals TSPT. The report states, “With an approved product, royalties that range from mid-teens to 40%, a multi-billion dollar market, and a skilled partner with deep pockets, we view TSPT (Market cap $94M) as one of the most undervalued stocks in the entire healthcare space. As per our analysis, Trancept announced that Purdue opted into the agreement to commercialize Intermezzo in the US.” TSPT closed yesterday at $6.97.